While it has been reported that p53 may enhance chemotherapeutic treatment in some cellular contexts [35], [36], our results suggest that p53-mediated cell cycle arrest/DNA damage repair is serving as a barrier to the desired clinical outcome of DNA damaging chemotherapy in ovarian cancer. Here, TP53 is linked to ovarian carcinoma.